Congratulations to the 28 applicants for the free trial stock
The follow-up stock related to ‘Coupang’ is coming out! Don’t miss it now. Seize the opportunity today.
The US FDA has designated the non-small cell lung cancer treatment new drug ‘Poziotinib’ as a Fast Track! This designation is to accelerate the development of a new drug that shows excellent efficacy for critically ill patients whose lives are at risk. Receiving support for research and development and enabling rapid commercialization, ‘this company’ is expected to gain more momentum in new drug development.
“I applied and bought small amounts every day for 3 days, and I was really surprised to see daily upper limit gains every day. It’s amazing how this is possible. It’s been about 3 months since I paid the membership fee and received VIP service, and already 30 million KRW has accumulated in my account. Thank you so much again. Ah! I am actively recommending it to my acquaintances as well.”
(VIP full-time housewife member, Mi-gyeong Lee, 54 years old)
Now think of this as your last chance. If you miss this opportunity, you have to give up.
Exactly on “March 15” it will explode! Don’t miss it and regret it, just buy at least 1 million KRW worth!
[AI recent upper limit hits]
*21.03.09 iCraft(052460) Up hit!
*21.03.04 NE Neungyule(053290) Up hit!
*21.03.02 HanbitSoft(047080) Up hit!
*21.02.26 KCT(089150) Up hit!
*21.02.24 Logisys(067730) Up hit!
*21.02.22 Medytox(086900) Up hit!
*21.02.19 Union(000910) Up hit!
*21.02.17 Danal(064260) Up hit!
*21.02.15 Dongbang(004140) 2 consecutive Up hits!
*21.02.10 Dongbang(004140) Up hit!
*21.02.08 Etron(096040) Up hit!
*21.02.05 SungAn(011300) Up hit!
*21.02.03 Gooyoung Tech(053270) Up hit!
*21.02.01 Hyosung TNC(298020) Up hit!
▶▶ Only 20 people will be accepted. “Monday upper limit”! ▶Receive now◀
※First-come, first-served 20 people closed! Both early and late rounds are over. The hero of the final injury time winning goal※
[Today’s stocks of interest]
#PrestigeBioPharma #DSCInvestment #BGF #HiteLron #TheraSem
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

